|Bid||0.0880 x 0|
|Ask||0.0890 x 0|
|Day's Range||0.0870 - 0.0940|
|52 Week Range||0.0150 - 0.1300|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.11|
Roby Zomer has been the CEO of MGC Pharmaceuticals Limited ( ASX:MXC ) since 2016, and this article will examine the...
Under the terms of this agreement, MGC Pharma will provide a comprehensive suite of pharmaceutical services to advance Allied’s pharmaceutical products into human clinical PHASE 1. The scope of MGC Pharma’s services will cover clinical research, IMP registration, manufacturing of lab volumes for the research project, drug stability testing, GMP manufacturing and regulatory assistance for obtaining an Investigational Medicinal Product (IMP) number that is needed in order to sell the pharmaceutical product. Allied has also conducted an extensive prior art review on its previously submitted provisional patents for products AC001 and AC002 and has decided to abandon these.
TORONTO and GLIL YAM, Israel , June 15, 2020 /CNW/ - IM Cannabis Corp. (the "Company" or "IMC") (IMCC.CN), one of the world's pioneering medical cannabis companies with operations in Israel and across Europe , today announced that the Company has signed a binding term sheet for the exclusive distribution rights of CannEpil® in Israel for a period of five years (the "Term Sheet"). The Term Sheet follows the announcement by MGC on May 26, 2020 that the Ethics Committee of Schneider Children's Medical Center of Israel has given its approval to commence a Phase IIb clinical trial of CannEpil® in Israel .